Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2017 07:00 ET | Source: Akorn, Inc.

Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance

- Q4 2016 Revenue Increase to $284 Million - - Q4 2016 GAAP Diluted EPS Decrease of 4% to $0.26; Q4 2016 Adjusted Diluted EPS Decrease of 3% to $0.58 - - FY 2016 Revenue Increase of 13% to $1,117...
February 28, 2017 17:30 ET | Source: Akorn, Inc.

Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP

LAKE FOREST, Ill., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug...
February 06, 2017 07:30 ET | Source: Akorn, Inc.

Akorn to Report Fourth Quarter and Full Year 2016 Results

LAKE FOREST, Ill., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on...
December 21, 2016 07:30 ET | Source: Akorn, Inc.

Akorn to Present at 35th Annual J.P Morgan Healthcare Conference

LAKE FOREST, Ill., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s CEO, Raj Rai, will present at the...
December 12, 2016 07:00 ET | Source: Akorn, Inc.

Akorn Announces Completion of FDA Re-inspection of Decatur Facility

LAKE FOREST, Ill., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) conducted...
November 29, 2016 07:30 ET | Source: Akorn, Inc.

Akorn Launches Ibuprofen Oral Suspension

LAKE FOREST, Ill., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has launched the prescription version of Ibuprofen...
November 28, 2016 17:15 ET | Source: Akorn, Inc.

Akorn Invalidates Durezol® Patent Via Inter Partes Review Proceeding

LAKE FOREST, Ill., Nov. 28, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that on November 22, 2016, the Patent Trial and Appeal...
November 16, 2016 08:30 ET | Source: Akorn, Inc.

Akorn to Present at Piper Jaffray 28th Annual Healthcare Conference

LAKE FOREST, Ill., Nov. 16, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that Akorn’s Chief Financial Officer, Duane...
November 03, 2016 07:05 ET | Source: Akorn, Inc.

Akorn Provides Third Quarter 2016 Results

- Q3 2016 Revenue Increase of 11% to $284 million - - Q3 2016 GAAP EPS of $0.38; Adjusted Q3 2016 EPS of $0.56 - - Updates 2016 Revenue, EPS and Adjusted EBITDA Guidance - - Repurchased $25 Million...
October 13, 2016 08:30 ET | Source: Akorn, Inc.

Akorn Announces Third Quarter 2016 Earnings Release and Conference Call Information

LAKE FOREST, Ill., Oct. 13, 2016 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on...